Physician profile
Leanne Almario
NPI 1619302684
$2,792.28
in general payments reported to CMS, 2019-2025
22 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.28 · 2020: $542 · 2021: $832 · 2022: $627 · 2023: $518 · 2024: $69.72 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $678 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $678.02 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,160.61 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Therapeuticsmd, INC. | $391.30 | 2019-2022 | |
| Hologic Sales and Service, LLC | $167.19 | 2020-2024 | Thinprep 2000 Processor, Aptima |
| Organon LLC | $155.64 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $142.44 | 2022-2023 | |
| Exeltis, USA INC. | $104.25 | 2020-2022 | |
| Pfizer INC. | $96.16 | 2020-2024 | |
| Amgen INC. | $86.34 | 2019-2020 | |
| Avion Pharmaceuticals | $69.96 | 2020-2022 | |
| Evofem Biosciences, INC. | $63.31 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.90 | 2021-2023 | |
| Agile Therapeutics, INC. | $51.09 | 2021-2023 | Twirla |
| Becton, Dickinson and Company | $49.45 | 2021-2023 | Bd Onclarity |
| Sumitomo Pharma America, INC. | $36.49 | 2023 | Myfembree |
| Mylan Pharmaceuticals INC. | $29.22 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| C. R. Bard, INC. & Subsidiaries | $28.14 | 2023 | Bd Onclarity |
| Karl Storz Endoscopy-America | $25.62 | 2020 | |
| Astellas Pharma US INC | $17.25 | 2024 | Veozah |
| Shield Therapeutics INC | $15.61 | 2022 | |
| Lupin INC. | $13.38 | 2020 | |
| Myovant Sciences INC. | $13.24 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.69 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leanne Almario listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.